http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
오국환 ( Kook Hwan Oh ),이성우 ( Seong Woo Lee ),박재윤 ( Jae Yoon Park ),정종철 ( Jong Cheol Jeong ),안신영 ( Shin Young Ahn ),박진주 ( Jin Joo Park ),서원우 ( Won Woo Seo ),김지훈 ( Chi Hoon Kim ),이사민 ( Sah Min Lee ),황진호 ( 대한신장학회 2010 Kidney Research and Clinical Practice Vol.29 No.6
Purpose: Peritoneal dialysis associated peritonitis (PD peritonitis) is an important complication in maintaining. There have been only a few reports on the clinical outcome of initial no-growth peritonitis (INGP). Methods: We reviewed 332 episodes of PD peritonitis between January 2002 and August 2009. INGP was defined as PD peritonitis with no growth of etiologic microorganism within 3 days of peritonitis. INGP was compared with initial positive growth peritonitis (IPGP) in view of clinical manifestations and outcomes. Results: We divided PD peritonitis episodes into two groups: INGP (n=90) and IPGP (n=242). Peritonitis-related mortality was 5.6 % in INGP, while 0.8 % in IPGP (p=0.017). Further relapse was noted in INGP (10.0%) than in IPGP (vs. 4.1%; p=0.041). Salvage antibiotics were used more frequently in INGP (21.1%) than in IPGP (vs. 11.6%; p=0.027). Odds ratio of INGP to IPGP for peritonitis-related mortality was 7.14 (95% CI 1.36-37.51; p=0.017). Growth of mycobacteria or fungi increased the risk of peritonitis-related mortality with an odds ratio of 18.11 (95% CI 2.99-109.89; p=0.013). In multivariate analysis, growth of mycobacteria or fungi was the only independent risk factor for peritonitis-related mortality with an odds ratio of 10.63 (95% CI 1.27-88.75; p=0.029). Conclusion: INGP revealed poorer outcome than IPGP. Higher growth rate of mycobacteria or fungi in INGP than in IPGP accounted for the poor outcome. Thus one should make vigorous efforts to detect surreptitious organism when there is no growth by 3 days, especially for the possibility of either mycobacteria or fungi.
건강검진을 받은 대상에서 만성 신질환의 빈도와 관련 이상
진호준 ( Ho Jun Chin ),오국환 ( Kook Hwan Oh ),오윤규 ( Yoon Kyu Oh ),나기영 ( Ki Young Na ),주권욱 ( Kwon Wook Joo ),임춘수 ( Chun Soo Lim ),김연수 ( Yon Su Kim ),채동완 ( Dong Wan Chae ),안규리 ( Cu Rie Ahn ),한진석 ( Jin Suk Ha 대한신장학회 2007 Kidney Research and Clinical Practice Vol.26 No.2
목적: 말기 신부전을 포함한 만성 신질환은 세계적으로 지속적으로 증가하고 있으며 사회적인 의료 부담을 증가시키고 있으나 국내에서는 만성 신질환에 대한 대규모 역학조사 결과가 없는 실정이다. 방법: 분당서울대학교 병원에서 최근 2년간 건강검진을 받은 18세 이상의 14,856명을 대상군으로 정하였다. 미국신장협회의 만성 신질환 진단기준을 이용하였으며 사구체 여과율은 수정된 MDRD 공식으로 계산하였다. 결과: 대상군의 평균 사구체 여과율은 83.3 mL/min/1.73 m2이었으며 연령이 10년 증가할 때마다 5.0 mL/min/1.73 m2씩 감소하였다. 만성 신질환 1기에 해당되는 대상군은 3.2% 이었고 2기와 3기 이상인 군은 각각 9.4%와 3.5%이었다. 만성 신질환의 빈도는 고혈압 혹은 당뇨가 있는 군에서 없는 군보다 많았다. 만성 신질환과 연관된 고혈압, 심혈관계 질환 병력, 고요산혈증, 고칼륨혈증, 고인산혈증과 고중성지방혈증은 사구체 여과율이 정상인 만성 신질환인 경우에서도 그 빈도가 신질환이 없는 군에 비하여 높았다. 만성 신질환을 가진 대상군에서 만성 신질환을 인지하고 있었던 경우는 6.3%이었으며, 혈압과 혈당이 비신질환자에 비하여 적절하게 조절되는 비율이 낮았다. 결론: 건강검진을 받은 대상자들에서 만성 신질환과 유관 질환은 의미있게 높게 조사되었으나 신질환에 대한 인지도와 적절한 혈압과 혈당이 유지되는 비율이 비신질환자에 비하여 낮았다. Purpose: The prevalence of chronic kidney disease (CKD) is increasing in Korea. Considerable resources have been consumed for patients with CKD. This study investigated the prevalence, the associated disorders, and the awareness of CKD and the current status of appropriate control for blood pressure and blood sugar in subjects with CKD. Methods: We included 14,856 subjects who underwent a health check-up in Seoul National University Bundang Hospital during the last 2 years. We selected K/DOQI guideline of CKD. We used the modified MDRD equation to estimate the glomerular filtration rate (eGFR). Results: The mean eGFR was 83.3 mL/min/1.73m2 and it decreased with aging at the rate of 5 (mL/min/1.73m2)/10 years. The prevalences of CKD stage 1, stage 2, and stage more than 3 were 3.2%, 9.4%, and 3.5%, respectively. The prevalence of CKD was higher in subjects with hypertension or diabetes mellitus than in subjects without it. The CKD was associated with disorders of hypertension, cardiovascular diseases, hyperuricemia, hyperphosphatenemia, hyperkalemia, and hypertriglyceridemia. The prevalence of reported kidney disease was only 6.5% in subjects with eGFR less than 60 mL/min/1.73m2. The frequency of adequate control of blood pressure and blood sugar in subjects with CKD was lower than in subjects without CKD. Conclusion: The subjects were rarely aware of CKD whereas the frequencies of CKD and the associated diseases were considerably high. We have to pay more attention to diagnose and treat the CKD.
임상 연구 : 지속적 정정맥 혈액투석여과법시행시 Amikacin 제거에 관한 약동학적 연구
문성용 ( Sung Yong Moon ),오국환 ( Kook Hwan Oh ),오윤규 ( Yoon Kyu Oh ),안규리 ( Cu Rie Ann ),주권욱 ( Kwon Wook Joo ),김연수 ( Yon Su Kim ),한진석 ( Jin Suk Han ),이정상 ( Jung Sang Lee ),김정렬 ( Jung Ryul Kim ),유경상 ( Kyung 대한신장학회 2006 Kidney Research and Clinical Practice Vol.25 No.4
김기원(Ki Won Kim),안규리(Cu Rie Ahn),오국환(Kook Hwan Oh),이경이(Kyung Yi Lee),이중건(Jung Geon Lee),오명돈(Myung Don Oh),김연수(Yon Su Kim),한진석(Jin Suk Han),김성권(Suhng Gwon Kim),이정상(Jung Sang Lee),장인진(In Jin Jang),신상구(Sa 대한신장학회 2002 Kidney Research and Clinical Practice Vol.21 No.1
N/A Background : Tuberculosis is more prevalent in dialysis patients than in the general population, and more difficult to make a diagnosis, and often leads to death, Moreover, extra-caution is needed in prescribing anti-tuberculosis medications as dose modification is frequently needed in patients with renal insufficiency. Several pharmacokinetic studies have been performed for antimycobacterial regimens in patients with renal insufficiency, including under hemodialysis. However, the anti-mycobacterial regimens of patients on peritoneal dialysis have been made based on empirical methods because of few pharmacokinetic studies. Methods : To elucidate the pharmacokinetic profiles of anti-mycobacterial regimens for peritoneal dialysis, we measured both plasma and peritosol concentrations of anti- tuberculous drugs including isoniazide, rifampin and pyrazinamide in 9 patients maintained on chronic ambulatory peritoneal dialysis(CAPD). Results : After a conventional oral dose of anti-tuberculosis medication, their plasma concentrations were in the therapeutic range, but the peritosol concentration of rifampin was below the therapeutic range. Conclusion : No dose adjustments are required for isoniazid, rifampin and pyrazinamide for the treatment of systemic or peritoneal tuberculosis in CAPD patients. On the contrary, oral rifampin is not expected to be effective in the treatment of tuberculous peritonitis, because of its low peritosol concentration. (Korean J Nephrol 2002; 21(1):67-73)